Summit Therapeutics

Pharma

Akeso, Summit’s ivonescimab hits OS goal in Keytruda head-to-head

Harmoni-2, which first sparked hopes for PD-1xVEGF drugs to replace Keytruda, is now the fourth phase 3 trial for ivonescimab to meet its OS endpoint.

Angus Liu Sep 3, 2026 10:29am

Akeso CEO touts biliary tract win, counters ivonescimab debate

Aug 26, 2026 11:11am

Generic tariffs, Samsung Bio, HK IPO—Fierce Pharma Asia

Jul 24, 2026 9:00am

Summit updates ivonescimab survival data ahead of PDUFA

Jul 22, 2026 10:58am

Akeso's 34% overall survival win comes with caveats

May 31, 2026 8:00am

mountain climb steep cliff climber struggle

Previewing Akeso's high-stakes ASCO plenary for PD-1/VEGF

May 27, 2026 11:25am